TECFIDERA

Type: Keyphrase
Name: TECFIDERA
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Xenoport's Path Is Long, But The Potential Is There

SummaryXenoPort appears to be taking a longer but clearer regulatory path for '829 in multiple sclerosis. Testing '829 in psoriasis is a valid approach for generating data germane to Phase III MS studies and could put a psoriasis indication into play. ... [Published Seeking Alpha - 4 hours ago]
First reported 15 hours ago - Updated 15 hours ago - 1 reports

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights Amgen ... [Published Motley Fool - 15 hours ago]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Tecfidera (dimethyl fumarate) from US biotech firm Biogen Idec (Nasdaq: ... [Published Pharma Letter - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 16 2014 - 1 reports

Is Biogen A Value Stock Yet?

By Bill Gunderson :Biogen Idec ( BIIB ) may be headquartered in Cambridge, Massachusetts, but it still has many ties to my hometown of San Diego. San Diego-based Idec Pharmaceuticals was acquired by Biogen in 2003 and it also has a key strategic partnership ... [Published BioPortfolio - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Surveyed European Neurologists Expect to Prescribe Biogen Idec's Tecfidera to 16 Percent of their Diagnosed Relapsing-Remitting Multiple Sclerosis Patients in the Next 12 Months

BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis ... [Published PR Newswire: General Business - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Biogen Idec to share latest neurology data at AAN 2014

:41 in Pharmaceutical Company Product News Biogen Idec has announced that it will be presenting new data on its current and future neurological disease therapies at the American Academy of Neurology (AAN) annual meeting. The company will attend the conference ... [Published Zenopa - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Researchers don’t know why some multiple sclerosis therapies work

Multiple sclerosis (MS) is a disease that attacks the nervous system causing an array of difficulties for those who suffer from it. From balance issues to vision problems, from incontinence to cognitive difficulties, the disease can take several different ... [Published Examiner.com - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting

- Two-Year Data from Pivotal Phase 3 ADVANCE Study for PLEGRIDY™ (Peginterferon Beta-1a) to Be Presented -- New TECFIDERA® (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients Treated ... [Published Benzinga.com - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Those who take LDN for MS, what dose do you take?

I have MS and will be starting LDN for the first time tonight. I just stopped Tecfidera as it gave me leukopenia (severe drop in WBC) and was too toxic (also have a HUGE concern it would eventually cause cancer). For those who take LDN for MS... what ... [Published HealthBoards - Apr 11 2014]
Entities: TECFIDERA, leukopenia, Toxic
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Sales of Biogens Tecfidera increase at faster clip than all but one drug

Biogen Idec's multiple sclerosis drug Tecfidera had the second-highest increase in sales from the third to the fourth quarter last year of any drug on the market. According ... ... [Published Big News Network - Apr 11 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 3 reports

Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland

07 April 2014Author: MS TrustThe Scottish Medicines Consortium (SMC) has approved dimethyl fumarate (BG-12, Tecfidera) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland.The MS Trust welcomes the decision by SMC. The MS ... [Published Multiple Sclerosis Trust - Apr 07 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 3 reports

Biogen Idec's Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch

PR NewswireBURLINGTON, Mass., March 19, 2014BURLINGTON, Mass.Other key findings from the TreatmentTrends: Multiple Sclerosis Q1 2014 (US) report:Comments from Decision Resources Group Senior Director Virginia SchobelAbout Decision Resources Group Decision ... [Published Digital Journal - Mar 19 2014]

Quotes

...lot in biotech, but it's also worth remembering a quote (apocryphally attributed to former Dallas Cowboys defensive lineman Randy White) that goes "potential is a fancy French word that means you haven't done yet"
...Dr Alfred Sandrock, group senior vice-president and chief medical officer at Biogen Idec, said: "The breadth of data we are presenting at AAN reinforces our enduring commitment to reducing the impact of multiple sclerosis and other serious neurodegenerative diseases." Earlier this month, the company announced the appointment of Dr Adam Koppel as its new senior vice-president and chief strategy officer, effective as...
"What is most intriguing about stopping natalizumab is the rebound activity that is often very severe and greater than that what was seen prior to starting natalizumab. Why? I suggest you read my  post from last year  on this topic; it generated a lot of discussion about MS and its potential cause."
...you look at the large-cap biotech group, it's very defensible," Citi Research managing director Yaron Werber said in an interview with CNBC Monday. "They are almost monopolies. They have great pipelines, and you have a lot of visibility under earnings for the next three to five years."

More Content

All (155) | News (95) | Reports (1) | Blogs (56) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Xenoport's Path Is Long, But The Potential Is T... [Published Seeking Alpha - 4 hours ago]
Earnings Primer: What's on Deck for Amgen Inc. ... [Published Motley Fool - 15 hours ago]
European neurologists expect Biogen Idec’s Tecf... [Published Pharma Letter - Apr 16 2014]
3 Biotech Opportunities Following This Selloff [Published Motley Fool Discussion Boards - Apr 16 2014]
Has healthcare embraced a hit-and-run strategy? [Published Forbes.com - Apr 16 2014]
Surveyed European Neurologists Expect to Prescr... [Published PR Newswire: General Business - Apr 15 2014]
Is Biogen A Value Stock Yet? [Published BioPortfolio - Apr 15 2014]
Biogen Idec to share latest neurology data at A... [Published Zenopa - Apr 15 2014]
Researchers don’t know why some multiple sclero... [Published Examiner.com - Apr 14 2014]
Biogen Idec to Present New Clinical Data from I... [Published Investor's Business Daily - Apr 14 2014]
Biogen to Present Clinical Data from Neurology ... [Published Benzinga.com - Apr 14 2014]
Those who take LDN for MS, what dose do you take? [Published HealthBoards - Apr 11 2014]
Sales of Biogens Tecfidera increase at faster c... [Published Big News Network - Apr 11 2014]
Sales of Biogen's Tecfidera increase at faster ... [Published Business First of Buffalo - Apr 10 2014]
Are Tapeworms The Conceptual Key To The Next Mu... [Published Seeking Alpha - Apr 10 2014]
Natalizumab to fingolimod washout in patients a... [Published Multiple Sclerosis Research - Apr 10 2014]
Alexion, Biogen Among Leading Big-Cap Biotechs [Published Investor's Business Daily - Apr 09 2014]
Biogen Idec and UCB Enter Agreements to Commerc... [Published FirstWord Pharma - Apr 09 2014]
Dimethyl fumarate (Tecfidera) approved in Scotland [Published Multiple Sclerosis Trust - Apr 08 2014]
IV azithromycin and Eviplera among medicines ap... [Published PJ Online - Apr 08 2014]
Biogen Idec May Have Seeds For Next-Gen MS Drugs [Published Investor's Business Daily - Apr 07 2014]
Dimethyl fumarate (BG-12, Tecfidera) approved f... [Published Multiple Sclerosis Trust - Apr 07 2014]
Tecfidera is approved by Scottish Medicines Con... [Published NewsRT.co.uk - Apr 07 2014]
Tecfidera is approved by Scottish Medicines Con... [Published Daily Record - Apr 07 2014]
New oral MS treatment Tecfidera approved for us... [Published MS News - Apr 07 2014]
Sanofi misled investors with rosy Lemtrada pred... [Published FiercePharma - Apr 07 2014]
Sanofi decides to take a second shot on Lemtrad... [Published FierceBiotech - Apr 07 2014]
Will Biogen Idec Inc. Rule Biotech in 2014? [Published Motley Fool Discussion Boards - Apr 03 2014]
Physician Views: Life-cycle management strategi... [Published MarketResearch.com - Apr 03 2014]
Gillenya [Published Multiple Sclerosis & Me - Apr 02 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Surveyed European Neurologists Expect to Prescr... [Published PR Newswire: General Business - Apr 15 2014]
BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis ...
Those who take LDN for MS, what dose do you take? [Published HealthBoards - Apr 11 2014]
I have MS and will be starting LDN for the first time tonight. I just stopped Tecfidera as it gave me leukopenia (severe drop in WBC) and was too toxic (also have a HUGE concern it would eventually cause cancer). For those who take LDN for MS... what ...
Natalizumab to fingolimod washout in patients a... [Published Multiple Sclerosis Research - Apr 10 2014]
Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven ...
New oral MS treatment Tecfidera approved for us... [Published MS News - Apr 07 2014]
The Scottish Medicines Consortium (SMC) has announced today that Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in Scotland. The Scottish medicines regulatory body reached its decision after reviewing the ...
Gillenya [Published Multiple Sclerosis & Me - Apr 02 2014]
Gilly!So...can't really say too much bout it yet but I'll say this. As long as I continue down this path of "no negative effects", I'll keep taking it. It has a number of things going for it and is better than Tecfidera (in my book).First of all, it's ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
ShangPharma nomme le dirigeant de l'industrie p... [Published PR Newswire - Oct 25 2013]
ShangPharma ernennt Führungskraft der Pharma-Br... [Published PR Newswire - Oct 25 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.